Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis
Corresponding Author
Alessandro Bucalossi
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Divisione di Ematologia, Ospedale A. Sclavo, Via Tufi 1, 53100 Siena, ItalySearch for more papers by this authorGiuseppe Marotta
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorCatia Bigazzi
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorPiero Galieni
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorEgidio Dispensa
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorCorresponding Author
Alessandro Bucalossi
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Divisione di Ematologia, Ospedale A. Sclavo, Via Tufi 1, 53100 Siena, ItalySearch for more papers by this authorGiuseppe Marotta
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorCatia Bigazzi
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorPiero Galieni
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorEgidio Dispensa
Division of Hematology, Hospital A. Sclavo, Siena, Italy
Search for more papers by this authorAbstract
Patients with polycythemia vera (PV) or essential thrombocythemia (ET) show a high frequency of thrombosis. The reduction of hematocrit after phlebotomy and normalization of platelet counts do not completely eliminate thrombotic risk. Some preliminary studies reported a reduction in the concentration of natural anticoagulants (NA) in this group of patients. For this reason we evaluated protein S (PS) total antigen, antithrombin III (AT III), and protein C (PC) activity in 81 patients with chronic myeloproliferative disorders (33 with PV and 48 with ET). Data were compared with those obtained in 70 healthy sex- and age-matched subjects. Fifty-seven percent of patients (46 out of 81) showed one or more thrombotic episodes at diagnosis or during follow-up. Interestingly, we found a NA deficit in 43.5% of patients with thrombosis versus only 5.7% in the group of patients without thrombosis. These results may suggest new interpretations about the pathogenesis of thrombosis in PV or ET patients. © 1996 Wiley-Liss, Inc.
References
- 1 Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR: Adverse effects of antiaggregating platelet therapy in the treatmnet of polycythemia vera. Semin Hematol 23: 172, 1986.
- 2 Mc Intyre KJ, Hoagland HC, Silverstein MN, Petitt RM: Essential thrombocythemia in young adults: Mayo Clin Proc 66: 149, 1991.
- 3 Spaet RH, Lejnieks I, Gaynor E, Goldstein ML: Defective platelets in essential thrombocythaemia. Arch Intern Med 124: 135, 1969.
- 4 Zucher S, Mielke CH: Classification of thrombocytosis based on platelet function tests: Correlation with hemorrhagic and thrombotic complications. J Lab Clin Med 80: 383, 1972.
- 5 Cortelazzo S, Viero P, Barbui T: Platelet activation in myeloproliferative disorders. Thromb Haemost 45: 211, 1981.
- 6 Pareti FI, Gugliotta L, Mannucci L, Guarini A, Mannucci PM: Bio-chemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost 47: 84, 1982.
- 7
Bellucci S,
Janvier M,
Tobelem G,
Flandrin G,
Charpak Y,
Berger R,
Boiron M:
Essential thrombocythemia: clinical evolutionary and biological data.
Cancer
58: 2440,
1986.
10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y PubMed Web of Science® Google Scholar
- 8
Fenaux P,
Simon M,
Caulier MT,
Lai JL,
Goudemaud J,
Bauters F:
Clinical course of essential thrombocythemia in 147 cases.
Cancer
66: 549,
1990.
10.1002/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6 PubMed Web of Science® Google Scholar
- 9
Lahuerta-Palacios JJ,
Bornstein R,
Fernandez-Debora FJ,
Gutierrez Rivas E,
Ortiz MC,
Larreqla S,
Calandre L,
Montero-Castillo J:
Controlled and uncontrolled thrombocytosis: its clinical role in essential thrombocythemia.
Cancer
61: 1207,
1988.
10.1002/1097-0142(19880315)61:6<1207::AID-CNCR2820610625>3.0.CO;2-4 PubMed Web of Science® Google Scholar
- 10 Pearson TC: Haematocrit, blood viscousity, cerebral blood flow, and vascular occlusion. In GDO Lowe (ed): “ Clinical Aspects of Blood Viscosity and Cell Deformability.” Berlin: Springer-Verlag, 1981.
- 11 Jabaily J, Iland H, Lazlo J, Massey EW, Faguet GB, Brière J, Landaw SA, Pisciotta AV: Neurolgic manifestations of essential thrombocy-themia. Ann Intern Med 99: 513, 1983.
- 12 Grossi A, Rossetti S, Vannucchi AM, Rafanelli D, Rossi Ferrini PL: Occurence of haemorrhagic and thrombotic events in myeloproliferative disorders: A retrospective study of 108 patients. Clin Lab Haematol 10: 167, 1988.
- 13
Hehlmann R,
Jahn M,
Ballmann B,
Kopcke W:
Essential thrombocythemia: Clinical characteristics and course of 61 cases.
Cancer
61: 2487,
1988.
10.1002/1097-0142(19880615)61:12<2487::AID-CNCR2820611217>3.0.CO;2-T PubMed Web of Science® Google Scholar
- 14 Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA, Marino GG: Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 33: 27, 1990.
- 15 Scherutharrer G, Ludwing M, Silberbauer K: Elevated plasma beta-thromboglobulin levels in multiple myeloma and polycythaemia vera. Acta Haemato 62: 219, 1979.
- 16 Oberild D, Hasselbalch H, Bjerreknudsen J: Platelet survival, platelet-factor 4 and bleeding time in myeloproliferative disorders. Scand J Clin Lab Invest 47: 497, 1987.
- 17 Tartaglia AP, Goldberg JD, Silverstein MN: Aspirin and persantine do not prevent thrombotic complications in patients with polycythemia vera treated with phlebotomy. Blood 58: 240a, 1981.
- 18 Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64: 1, 1984.
- 19 Barbui T: Clinical epidemiology of thrombosis in 1213 patients with polycythemia vera (PV). Is a clinical trial of antithrombotic drugs feasible? Blood 84: 57a, 1994.
- 20 Burge PS, Johnson WS, Prankerd TAJ: Morbidity and mortality in pseudopolycythemia. Lancet 1: 1266, 1975.
- 21 Weinreb NJ, Shih CF: Spurious polycythemia. Semin Hematol 12: 397, 1975.
- 22 Thomas DJ, Marshall J, Russell RSR, Wetherly-Mein G, du Boulay GH, Pearson TC, Symon L, Zilkha E: Effect of haematocrit on cerebral blood-flow in man. Lancet 2: 941, 1977.
- 23 Thomas DJ, Marshall J, Russell RWR, Wetherly-Mein G, du Boulay GH, Pearson TC, Symon L, Zilkha E: Cerebral blood-flow in polycythemia. Lancet 2: 161, 1977.
- 24 Pearson TC, Wetherley-Mein G: Vascular occlusive episodes and venous haematocrit in primary proliferative polycythemia. Lancet 2: 1219, 1978.
- 25 Pearson TC, Wetherley-Mein G: The course and complications of idiopathic crythrocytosis. Clin Lab Haematol 1: 189, 1979.
- 26 Humphrey PRD, Marshall J, Russell RWR, Wetherley-Mein G, du Boulay GH, Pearson TC, Symon L, Zilkha E: Cerebral blood-flow and viscosity in relative polycythemia. Lancet 2: 873, 1979.
- 27 Conlan MG, Haire WD: Low protein S in essential thrombocythaemia with thrombosis. Am J Hematol 32: 88, 1989.
- 28 Zoppi M, Furlan M, Brun Del Re G, Wuillemin W, Lammle B: Decreased free protein S levels in polycythemia vera. Thromb Haemost 64: 177, 1990.
- 29 Holding S, Smith J, Kendal C, Picksley S: Acquired coagulation defects in myeloproliferative disorders. Thromb Haemost 65: 1018, 1991.
- 30 Wieczorek I, MacGregor IR, Prescott RJ, Ludlam CA: The fibrinolytic system and protein C and S in treated polycythemia rubra vera. Blood Coagul Fibrinolysis 3: 823, 1992.
- 31 Wieczorek I, Ludlam CA, Mac Gregor IR: Essential thrombocythaemia. More insight into the pathogenesis of thrombosis. Br J. Jaematol 80: 13, 1992.
- 32 Bazzan M, Tamponi G, Gallo E, Stella S, Schinco PC, Pannocchia A, Pileri A: Fibrinolytic imbalance in essential thrombocythemia: Role of platelets. Haemostasis 23: 38, 1993.
- 33 Holding S: Incidence of adquired prethrombotic defects in the myeloproliferative disorders. Thromb Haemost 69: 1218, 1993.
- 34 Mazzucconi MG, Chistolini A, Ferrari A, Arcieri P, Mandelli F: Level of protein S and essential thrombocythemia. Am J Hematol 36: 73, 1991.
- 35 Bellucci S, Ignatova E, Jaillet N, Boffa MC: Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 70: 736, 1993.
- 36 Berlin N: Diagnosis and classification of the polycythemias. Semin Hematol 12: 339, 1975.
- 37 Mitus AJ, Schafer AI: Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 4: 157–158, 1990.
- 38 Tripodi A, Bertina RM, Conard J, Pabinger I, Sala N, Mannucci PM: Multicenter evaluation of three commerical methods for measuring protein S antigen. Thromb Haemost 68: 149, 1992.
- 39 de Ronde H, Bertina RM: Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72: 880, 1994.
- 40 Andrew M, Vegh P, Johnston M. Bowker J, Ofosu F, Mitchell L: Maturation of the hemostatic system during childhood. Blood 80: 1998, 1992.
- 41 Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Wight M, Mitchell R, Davidson JF: Protein C activity in healthy volunteers. Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 70: 281, 1993.
- 42 Dolan G, Neal K, Cooper P, Brown P, Preston FE: Protein C, antithrombin III and plasminogen: Effect of age, sex and blood group. Br J Haematol 86: 798, 1994.
- 43 Wintrobe MM: Macroscopic examination of the blood. Am J Med Sci 185: 58, 1933.
- 44 Murphy S, Iland H, Rosenthal D, Laslo J: Essential thrombocythemia: An interim report form the Polycythemia Vera Study Group. Semin Hematol 23: 177, 1986.
- 45 Van De Pette J, Prochazka AV, Pearson TC, Singh AK, Dikson ER, Wetherley-Mein G: Primary thrombocythaemia treated with busulphan. Br J Haematol 62: 229, 1986.
- 46
Fenaux P,
Simon M,
Cauklier MT,
Lai JL,
Goudeman J,
Bauters F:
Clinical course of essential thrombocythemia in 147 cases.
Cancer
66: 549,
1990.
10.1002/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6 PubMed Web of Science® Google Scholar
- 47 Rodeghiero F, Ruggeri M, Tosetto A, Dini E: Trombocitemia essenziale: Aspetti clinici. Haematologica 76: 361, 1991.
- 48 Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23: 132, 1986.
- 49 Singh AK, Wetherley-Mein G: Microvascular occlusive lesions in primary thrombocythemia. Br J Haematol 36: 553, 1977.
- 50 Buss DH, Stuart JJ, Lipscomb GE: The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases. Am J Hematol 20: 365, 1985.
- 51 Stella S, Foli C, Vaccarino A, Ciocca Vasino A, Resegotti L, Tamponi G, Pileri A, Bazzan M: Rapporto fra numero di piastrine e fibrinolisi plasmatica in pazienti contrombocitemia essenziale. In XIII Congresso della Societ̀a Italiana Studio Emostasi e Trombosi, 1994, abstract 275.
- 52 Levy VG, Ruskone A, Baillou C, Thierman-Duffaud D, Najman A, Boffa GA: Polycythemia and the Budd-Chiari syndrome: Study of erythropoietin and bone marrow erythroid progenitors. Hepathology 5: 858, 1985.
- 53 Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Paziente EA, Leporrier M, Rueff B, Muller O, Benhaman JP: Primary myeloproliferative disorder and hepatic vein thrombosis. A prostpective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 103: 329, 1985.
- 54 Teofili L, De Stefano V, Leone G, Micalizzi P, Iovino MS, Alfano G, Bizzi B: Hematological causes of venous thrombosis in young people: High incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemost 67: 297, 1992.
- 55 Watson KV, Key N: Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors. Br J Haematol 83: 198, 1993.
- 56 Rogers II JS, Murgo AJ, Fontana JA, Raich PC: Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6: 276, 1988.
- 57
Feffer SE,
Carmosino LS,
Fox RL:
Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate and 5-fluorouracil.
Cancer
63: 1303,
1989.
10.1002/1097-0142(19890401)63:7<1303::AID-CNCR2820630713>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 58 Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM: Naturally occurring antico-agulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood 81: 3458, 1993.
- 59 Mitchell CA, Salem HH: Cleavage of protein S by a platelet membrane protease. J Clin Invest 79: 374, 1987.
- 60 Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C: Acquired protein S deficiency: Correlation with advanced disease in HIV-1 infected patients. J Acquired Immune Defic Syndr 51: 484, 1992.
- 61 Griffin JH, Evatt B, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82: 1989, 1993.
- 62 Schafer AI: The hypercoagulable states. Ann Intern Med 102: 814, 1985.